Search results for "double-blind"

showing 10 items of 662 documents

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (E…

2015

Summary Background Alisporivir (ALV) is an oral, host-targeting agent with pangenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Aim To evaluate efficacy and safety of ALV plus peginterferon-α2a and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection. Methods Double-blind, randomised, placebo-controlled, Phase 3 study evaluating ALV 600 mg once daily [response-guided therapy (RGT) for 24 or 48 weeks or 48 weeks fixed duration] or ALV 400 mg twice daily RGT with PR, compared to PR alone. Following a Food and Drug Administration partial clinical hold, ALV/placebo was discontinued and patients completed treatment with PR only. At that…

MalePhases of clinical researchHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundMedicinePharmacology (medical)ChronicAlisporivirAdolescent; Adult; Aged; Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young AdultGastroenterologyHepatitis CRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeCombinationCyclosporineDrug Therapy CombinationFemaleHumanUnited StateAdultmedicine.medical_specialtyAdolescentGenotypeAlpha interferonPlaceboAntiviral AgentsYoung AdultDrug TherapyDouble-Blind MethodInternal medicineRibavirinHumansAdverse effectAgedAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterferon-alphaHepatitis C Chronicmedicine.diseaseUnited StatesRegimenchemistryImmunologybusinessAlimentary pharmacologytherapeutics
researchProduct

Effect of cholinergic stimulation in early Alzheimer's disease - functional imaging during a recognition memory task.

2011

Treatment of Alzheimer's disease (AD) with acetylcholinesterase inhibitors (AChEI) enhances cholinergic activity and alleviates clinical symptoms. In the present functional magnetic resonance imaging (fMRI) study, we investigated the effect of the AChEI rivastigmine on cognitive function and brain activation patterns during a face recognition memory task. Twenty patients with newly-diagnosed mild AD were administered a single oral dose of placebo, a single dose of rivastigmine (acute), and twice-daily treatment with rivastigmine for 4 weeks (chronic). After each treatment, the patients underwent a facial recognition task during fMRI. The prefrontal areas known to be involved in face recogni…

MalePhenylcarbamatesRivastigmineBrain mappingDouble-Blind MethodAlzheimer DiseaseMemorymedicineImage Processing Computer-AssistedHumansPrefrontal cortexCognitive reserveRecognition memoryAgedRivastigmineBrain Mappingmedicine.diagnostic_testWorking memoryCognitionMagnetic Resonance ImagingNeurologyPattern Recognition VisualFemaleNeurology (clinical)Cholinesterase InhibitorsFunctional magnetic resonance imagingPsychologyNeurosciencemedicine.drugCurrent Alzheimer research
researchProduct

Anodal transcranial direct current stimulation and intermittent theta-burst stimulation improve deglutition and swallowing reproducibility in elderly…

2019

Background: Dysphagia in the elderly, known as presbydysphagia, has become a relevant public health problem in several countries. Swallowing disorders may be a consequence of different neurological disorders (secondary presbydysphagia) or the expression of the aging process itself (primary presbydysphagia). We aimed to test the therapeutic potential of two different non-invasive brain stimulation (NIBS) techniques in subjects with primary or secondary presbydysphagia. Methods: A blinded randomized controlled trial with crossover design was carried out in 42 patients, randomly assigned to anodal transcranial direct current stimulation (tDCS) or intermittent theta-burst stimulation (TBS) grou…

MalePhysiologymedicine.medical_treatmentbrain stimulationStimulationTranscranial Direct Current StimulationtDCSlaw.invention030507 speech-language pathology & audiology03 medical and health sciences0302 clinical medicineSwallowingRandomized controlled trialDouble-Blind MethodlawmedicineHumansTBSProspective StudiesAgedCross-Over StudiesTranscranial direct-current stimulationEndocrine and Autonomic Systemsbusiness.industrySwallowing DisordersGastroenterologyMotor CortexCrossover studyDysphagiaDeglutitionTreatment OutcomepresbydysphagiaBrain stimulationAnesthesiaTMSFemalemedicine.symptom0305 other medical sciencebusinessDeglutition Disorders030217 neurology & neurosurgery
researchProduct

Effects of caffeine on neuromuscular function in a non‐fatigued state and during fatiguing exercise

2020

New findings What is the central question of the study? What are the effects of caffeine on neuromuscular function in a non-fatigued state and during fatiguing exercise? What is the main finding and its importance? In a non-fatigued state, caffeine decreased the duration of the silent period evoked by transcranial magnetic stimulation. Caffeine-induced reduction of inhibitory mechanisms in the central nervous system before exercise was associated with an increased performance. Individuals who benefit from caffeine ingestion may experience lower perception of effort during exercise and an accelerated recovery of M-wave amplitude postfatigue. This study elucidates the mechanisms of action of …

MalePhysiologyväsymysmedicine.medical_treatmentliikunta030204 cardiovascular system & hematologyRC1200H-Reflexchemistry.chemical_compound0302 clinical medicineTriceps surae muscletranscranial magnetic stimulationMedicinerasitusMotor NeuronsNutrition and DieteticsMotor CortexGeneral MedicineTranscranial Magnetic Stimulationhermo-lihastoimintamedicine.anatomical_structureNeuromuscular AgentsMuscle FatigueCaffeineMuscle ContractionAdultmedicine.medical_specialtyQP301.H75_Physiology._Sport.Postureperipheral fatiguePlacebo03 medical and health sciencesPhysical medicine and rehabilitationDouble-Blind MethodCaffeinePhysiology (medical)Humansrate of perceived exertionExercisesoleussuorituskykySoleus musclePyramidal tractsbusiness.industryEvoked Potentials MotorQPCrossover studycentral fatigueTranscranial magnetic stimulationchemistrykofeiiniSilent periodbusiness030217 neurology & neurosurgeryExperimental Physiology
researchProduct

Efficacy of Subgingival Irrigation Using Herbal Extracts on Gingival Inflammation

2003

The aim of the present study was to investigate the efficacy of an herbal-based mouthrinse in combination with an oral irrigator in reducing gingival inflammation.A total of 89 patients (45 females, 44 males; mean age 49.1 +/- 1.31 years) were included in this prospective, randomized, double-blind clinical study and allocated to 3 treatment groups: group 1 (n = 34), treated with an oral irrigator with subgingival tips and an herbal-based mouthrinse; group 2 (n = 29), the oral irrigator was applied in combination with a conventional mouthwash; and group 3 (n = 26), treated with the conventional mouthwash without subgingival irrigation. Data collected at baseline and after 4, 8, and 12 weeks …

MalePlaque indexHerbal extractsMouthwashesDentistryClinical studyDouble-Blind MethodSubgingival irrigationHumansPeriodontal PocketMedicineProspective StudiesGingival inflammationTherapeutic IrrigationAnalysis of VariancePlant Extractsbusiness.industryDental Plaque IndexMean ageMiddle AgedPlantsOral HygieneGingivitisGingival indexSodium BicarbonatePeriodonticsFemalePeriodontal IndexGingival HemorrhageOral irrigatorbusinessFollow-Up StudiesJournal of Periodontology
researchProduct

The MITOS system predicts long-term survival in amyotrophic lateral sclerosis

2015

ObjectiveThe choice of adequate proxy for long-term survival, the ultimate outcome in randomised clinical trials (RCT) assessing disease-modifying treatments for amyotrophic lateral sclerosis (ALS), is a key issue. The intrinsic limitations of the ALS Functional Rating Scale-Revised (ALSFRS-R), including non-linearity, multidimensionality and floor-effect, have emerged and its usefulness argued. The ALS Milano-Torino staging (ALS-MITOS) system was proposed as a novel tool to measure the progression of ALS and overcome these limitations. This study was performed to validate the ALS-MITOS as a 6-month proxy of survival in 200 ALS patients followed up to 18 months.MethodsAnalyses were performe…

MalePredictive Value of TestWalkingLogistic regressionALS; MOTOR NEURON DISEASE; NEUROMUSCULAR; RANDOMISED TRIALS; Adult; Aged; Amyotrophic Lateral Sclerosis; Communication; Deglutition; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Noninvasive Ventilation; Predictive Value of Tests; ROC Curve; Respiration; Self Care; Survival Analysis; Walking; Neurology (clinical); Psychiatry and Mental Health; Surgery; Arts and Humanities (miscellaneous); Medicine (all)law.inventionALS long-term survival ALSFRS-RDisability EvaluationRandomized controlled triallawNEUROMUSCULARAmyotrophic lateral sclerosisMOTOR NEURON DISEASEALS; MOTOR NEURON DISEASE; NEUROMUSCULAR; RANDOMISED TRIALS; Neurology (clinical); Psychiatry and Mental Health; Surgery; Arts and Humanities (miscellaneous)CommunicationRespirationMedicine (all)Area under the curveMiddle Agedals motor neuron disease neuromuscular randomised trialsPsychiatry and Mental HealthPredictive value of testsDisease ProgressionSettore MED/26 - NeurologiaFemaleSurvival AnalysiHumanAdultmedicine.medical_specialtyNOSwallowingDouble-Blind MethodArts and Humanities (miscellaneous)Predictive Value of TestsInternal medicinemedicineRANDOMISED TRIALSHumansSurvival analysisAgedNoninvasive VentilationReceiver operating characteristicbusiness.industryAmyotrophic Lateral Sclerosisals; motor neuron disease; neuromuscular; randomised trials; adult; aged; amyotrophic lateral sclerosis; communication; deglutition; disability evaluation; disease progression; double-blind method; female; humans; male; middle aged; noninvasive ventilation; predictive value of tests; roc curve; respiration; self care; survival analysis; walking; neurology clinical; psychiatry and mental health; surgery; arts and humanities ; medicinemedicine.diseaseSurvival AnalysisSurgeryDeglutitionSelf CareALS; MOTOR NEURON DISEASE; NEUROMUSCULAR; RANDOMISED TRIALS; Adult; Aged; Amyotrophic Lateral Sclerosis; Communication; Deglutition; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Noninvasive Ventilation; Predictive Value of Tests; ROC Curve; Respiration; Self Care; Survival Analysis; Walking; Surgery; Arts and Humanities (miscellaneous); Neurology (clinical); Psychiatry and Mental HealthROC CurveSurgeryNeurology (clinical)ALSbusinessAmyotrophic Lateral Sclerosi
researchProduct

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with che…

2013

Abstract Introduction Tigatuzumab, a humanized monoclonal DR5 agonist antibody induces apoptosis in human cancer cell lines. The objective of this study was to investigate the antitumor effects of tigatuzumab combined with carboplatin/paclitaxel in chemotherapy-naive patients with metastatic/unresectable non-small cell lung cancer (NSCLC). Methods Patients with histologically or cytologically confirmed NSCLC stage IIIB/IV disease by RECIST (version 1.0) and ECOG-PS 0–1 were enrolled at 15 European sites. Patients received tigatuzumab or placebo intravenously with carboplatin/paclitaxel every 3 weeks (1 cycle) for up to 6 cycles. The primary end point was progression-free survival (PFS). Sec…

MalePulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPaclitaxelmedicine.medical_treatmentPhases of clinical researchNeutropeniaAntibodies Monoclonal HumanizedPlaceboGastroenterologyDisease-Free SurvivalCarboplatinPlaceboschemistry.chemical_compoundDouble-Blind MethodCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisTigatuzumabLung cancerNeoplasm StagingChemotherapybusiness.industryMiddle Agedmedicine.diseaseCarboplatinSurgeryEuropeReceptors TNF-Related Apoptosis-Inducing LigandOncologychemistryPaclitaxelFemalebusinessLung Cancer
researchProduct

Beneficial effects of C1 esterase inhibitor in ST-elevation myocardial infarction in patients who underwentsurgical reperfusion: a randomized double-…

2007

Background: The inflammatory cascade has been hypothesized to be an important mechanism of post-ischaemic myocardial reperfusion injury and several studies demonstrated that C1 esterase inhibitor (C1 -INH) is effective in post-ischaemia myocardial protection. Therefore, we aimed to investigate prospectively in a randomised double-blind study the cardioprotective effects of C1-INH in ST segment elevation myocardial infarction (STEMI) in patients who underwent emergent reperfusion with coronary artery bypass grafting (CABG). Methods: In this study, we enrolled 80 patients affected with STEMI who underwent emergent CABG. Patients were assigned in two groups (C1-INH group: receive 1000 Ul of C1…

MalePulmonary and Respiratory MedicineCardiac function curvemedicine.medical_specialtyMean arterial pressureCardiotonic AgentsMyocardial InfarctionCardiac indexMyocardial ReperfusionComplement C1 Inactivator ProteinsCoronary artery bypass surgeryReperfusion therapyDouble-Blind MethodInternal medicinemedicineHumansProspective StudiesMyocardial infarctionCoronary Artery BypassInfusions IntravenousSTEMI patients CABG C1 esterase inhibitor Reperfusion injury Complement cascade Myocardial function recoverybusiness.industryST elevationTroponin IComplement C4aGeneral MedicineMiddle Agedmedicine.diseaseMyocardial ContractionComplement Inactivating AgentsTreatment OutcomeComplement C3aCardiologyFemaleSurgeryCardiology and Cardiovascular MedicinebusinessReperfusion injury
researchProduct

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with mod…

2015

Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium for the treatment of COPD. The QUANTIFY study compared QVA149 with a free-dose bronchodilator combination of tiotropium plus formoterol (TIO+FOR) in improving health-related quality of life (HRQoL) of patients with COPD. Methods This multicentre, blinded, triple-dummy, parallel-group, non-inferiority study randomised patients aged ≥40 years with moderate-to-severe COPD (post-bronchodilator forced expiratory volume in 1 s (FEV1) ≥30% to <80% predicted) to QVA149 110/50 µg o.d. or TIO 18 µg o…

MalePulmonary and Respiratory MedicineVital capacitymedicine.drug_classChronic Obstructive Pulmonary DiseaseVital CapacityScopolamine DerivativesQuinolonesCOPD PharmacologyDrug Administration SchedulePulmonary Disease Chronic ObstructiveFEV1/FVC ratioDouble-Blind MethodQuality of lifeForced Expiratory VolumeFormoterol FumarateBronchodilatorHumansMedicine1506Tiotropium BromideAdrenergic beta-2 Receptor AgonistsAgedCOPDbusiness.industryMiddle Agedmedicine.diseaseGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeEthanolaminesBronchodilator AgentsAnesthesiaIndansQuality of LifeIndacaterolFemaleFormoterolbusinessmedicine.drugThorax
researchProduct

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study

2011

SummaryBackgroundIndacaterol is a novel, inhaled once-daily ultra-long-acting β2-agonist for the treatment of COPD.MethodsThis 12-week randomised, parallel-group study compared the efficacy of indacaterol 150 μg once-daily to salmeterol 50 μg twice-daily in patients with moderate-to-severe COPD. Assessments included FEV1 standardised area under curve (AUC) from 5 min to 11 h 45 min at Week 12 (primary endpoint), 24-h trough FEV1 (mean of 23 h 10 min and 23 h 45 min post-dose) at Week 12 (key secondary endpoint), FEV1 and FVC measured over 24-h, transition dyspnoea index (TDI) and rescue medication use.ResultsOf 1123 patients randomised 92.1% completed. Mean ± SD age was 62.8 ± 8.78 years, p…

MalePulmonary and Respiratory Medicinemedicine.drug_classbeta2-agonistQuinolonesDrug Administration Schedulelaw.inventionFEV1/FVC ratioPulmonary Disease Chronic ObstructiveRandomized controlled trialDouble-Blind MethodlawBronchodilatorForced Expiratory VolumeClinical endpointmedicineCOPDHumansAlbuterolSalmeterolSalmeterol XinafoateIndacaterolCOPDDose-Response Relationship Drugbusiness.industryrespiratory systemMiddle Agedmedicine.diseaserespiratory tract diseasesBronchodilator AgentsRespiratory Function TestsTreatment OutcomeAnesthesiaIndansIndacaterolFemaleSalmeterolOnce dailybusinessBronchodilatormedicine.drugRespiratory Medicine
researchProduct